An HCV NS5A inhibitor.

An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) monoclonal antibody; immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer; it is used to treat MULTIPLE SCLEROSIS.

A pan-ERBB inhibitor.

NCI: An orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells. EGFRs play major roles in tumor cell proliferation and tumor vascularization, and are often overexpressed or mutated in various tumor cell types. (NCI Thesaurus)

A pan-ERBB inhibitor.

NCI: An orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells. EGFRs play major roles in tumor cell proliferation and tumor vascularization, and are often overexpressed or mutated in various tumor cell types. (NCI Thesaurus)

Related to fortimicin A.

A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)

Antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR.

Antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR.